United Therapeutics Corporation (NASDAQ:UTHR) Shares Bought by Natixis Advisors LLC

Key Points

• Natixis Advisors LLC significantly increased its stake in United Therapeutics Corporation by 763.4%, acquiring an additional 104,847 shares, bringing its total holdings to approximately $36.56 million.
• Multiple hedge funds have modified their positions in United Therapeutics, with a total of 94.08% of the stock now owned by institutional investors and hedge funds.
• Despite a year-over-year revenue increase of 11.7%, United Therapeutics reported an EPS of $6.41, missing expectations by $0.39 during its last quarterly earnings report.

Natixis Advisors LLC grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 763.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 118,582 shares of the biotechnology company's stock after acquiring an additional 104,847 shares during the period. Natixis Advisors LLC owned about 0.26% of United Therapeutics worth $36,556,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. LPL Financial LLC boosted its position in shares of United Therapeutics by 122.8% in the 4th quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock worth $5,024,000 after buying an additional 7,847 shares in the last quarter. Orion Portfolio Solutions LLC raised its position in United Therapeutics by 22.4% during the fourth quarter. Orion Portfolio Solutions LLC now owns 4,021 shares of the biotechnology company's stock worth $1,419,000 after acquiring an additional 735 shares during the last quarter. Allstate Corp purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $415,000. O Shaughnessy Asset Management LLC grew its position in shares of United Therapeutics by 6.2% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 3,930 shares of the biotechnology company's stock valued at $1,387,000 after purchasing an additional 228 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in shares of United Therapeutics by 31.4% in the fourth quarter. Franklin Resources Inc. now owns 329,379 shares of the biotechnology company's stock valued at $116,218,000 after purchasing an additional 78,660 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on UTHR shares. JPMorgan Chase & Co. cut their price objective on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company cut their price target on United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating for the company in a report on Thursday. Bank of America reduced their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. HC Wainwright set a $400.00 price objective on United Therapeutics and gave the stock a "buy" rating in a research report on Thursday. Finally, Wall Street Zen lowered shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $379.69.

Insider Transactions at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director owned 19,384 shares in the company, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nilda Mesa sold 645 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director directly owned 4,883 shares of the company's stock, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 70,681 shares of company stock valued at $21,318,359. Corporate insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of UTHR stock opened at $274.70 on Friday. The firm's 50-day simple moving average is $298.39 and its 200-day simple moving average is $314.07. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $417.82. The firm has a market cap of $12.39 billion, a P/E ratio of 10.72, a PEG ratio of 6.15 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The business's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period last year, the company posted $5.85 EPS. Analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.